Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC

Takayuki Yoshino, MD, PhD , National Cancer Center Hospital, Chiba, Japan, shares results of the Phase III PARADIGM trial (NCT02394795) investigating anti-EGFR panitumumab antibody plus mFOLFOX6 versus the anti-VEGFR bevacizumab antibody plus mFOLFOX6 as first-line treatment in patients with left-sided RAS wild-type metastatic colorectal cancer (mCRC). The primary endpoint of the PARADIM trial was overall-survival (OS) and secondary endpoints included progression-free survival (PFS), response rate (RR) and duration of response (DOR). This Phase III study demonstrated a superior OS rate with panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Transcript (edited for clarity)

PARADIGM is the first prospective clinical study to test the superiority of Panitumumab over Bevacizumab, in combination with the standard chemo modified FOLFOX-6 treatment in patients with RAS wild-type metastatic colorectal cancer. The findings in the primary endpoint is that the overall survival in the left-sided population, if positive result, we move the whole world to test overall survival in the overall population, to define both the left-sided and the right-sided population, hierarchical way...

PARADIGM is the first prospective clinical study to test the superiority of Panitumumab over Bevacizumab, in combination with the standard chemo modified FOLFOX-6 treatment in patients with RAS wild-type metastatic colorectal cancer. The findings in the primary endpoint is that the overall survival in the left-sided population, if positive result, we move the whole world to test overall survival in the overall population, to define both the left-sided and the right-sided population, hierarchical way.

So, results show we got the survival benefit primary endpoint met in the left-sided population as well as the right-sided population, with hazard ratio around 0.80, so favoring the Panitumumab over Bevacizumab. So, second endpoints showing the standard response rate and R0 curative resection rate is very high in Panitumumab over Bevacizumab.

So, in conclusion, my presentation is that a new standard care of the Panitumumab modified FOLFOX-6 treatment, over Bevacizumab modified FOLFOX-6, in patients with RAS wild-type left-sided tumor population.

Read more...